A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets
Posted
Frank Vinluan (via MedCity News)
NeOnc Technologies is preparing to go public via the less common path of a direct listing as it continues mid-stage testing of its intranasally administered brain cancer drug. Meanwhile, the mostly stagnant biotech IPO pipeline is showing new signs of life with two large stock market debuts expected this week.
The post A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets appeared first on MedCity News.
BioPharma,
Daily,
Pharma,
biotech IPO,
brain cancer,
Clinical Trials,
direct listing,
glioblastoma,
NeOnc Technologies,
Thomas Chen,
University of Southern California
